Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
NT$ 7.27
Key Takeaways
Risk factor
Very poor trading liquidity
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Holy Stone Healthcare Co., Ltd. engages in the research, development and manufacture of hyaluronic acid drugs and medical devices. It offers injectable devices for osteoarthritis and soft tissue injuries. The company also provides hyaluronic acid and mesalamine capsules for inflammatory bowel diseases. Holy Stone Healthcare was founded on January 18, 2001 and is headquartered in...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Data is available to registered users only
Buy
Sell